Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

1.410 -0.090 (-6.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aptevo Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 Next >
TOMI Environmental Solutions (NASDAQ: TOMZ): The Next Era of Disinfection Technology – More Stocks Inside
Via AB Newswire
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
Via ACCESS Newswire
Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
Via ACCESS Newswire
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update
Via ACCESS Newswire
100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial
Via ACCESSWIRE
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
Via ACCESS Newswire
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update
Via ACCESS Newswire
Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESS Newswire
Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects
Via ACCESSWIRE
Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers
Via ACCESS Newswire
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules
Via ACCESS Newswire
Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML
Via ACCESS Newswire
Aptevo Participating in the BIO International Convention
Via ACCESS Newswire
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan
Via ACCESS Newswire
Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig
Via ACCESS Newswire
Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation
Via ACCESS Newswire
Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
$2 Stocks to Watch: PNPN.V, TIVC, APVO, OSRH, PRSO Biotech Breakthroughs, MedTech Momentum Metallic Metals Power Play & Signal Innovation
Via AB Newswire
Topics Intellectual Property
Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Via ACCESS Newswire
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
Via ACCESS Newswire
Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy
Via ACCESS Newswire
Aptevo to Participate in March Conferences
Via ACCESS Newswire
Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025
Via ACCESSWIRE
Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds
Via ACCESSWIRE
Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.